RT journal article T1 HTLV-1 infection in solid organ transplant donors and recipients in Spain A1 de Mendoza, Carmen A1 Roc, Lourdes A1 Benito, Rafael A1 Reina, Gabriel A1 Ramos, José Manuel A1 Gómez, César A1 Aguilera, Antonio A1 Rodríguez Iglesias, Manuel Antonio A1 García Costa, Juan A1 Fernández Alonso, Miriam A1 Soriano, Vicente A2 Bioquímica y Biología MolecularMicrobiología, Medicina Preventiva, Salud Pública K1 HTLV-1 K1 Transplantation K1 Screening K1 Tropical spastic paraparesis K1 Adult T-cell leukaemia K1 Immunosuppression AB Background: HTLV-1 infection is a neglected disease, despite infecting 10–15 million people worldwide andsevere illnesses develop in 10% of carriers lifelong. Acknowledging a greater risk for developing HTLV-1associated illnesses due to immunosuppression, screening is being widely considered in the transplantationsetting. Herein, we report the experience with universal HTLV testing of donors and recipients of solid organtransplants in a survey conducted in Spain.Methods: All hospitals belonging to the Spanish HTLV network were invited to participate in the study. Briefly, HTLVantibody screening was performed retrospectively in all specimens collected from solid organ donors and recipientsattended since the year 2008.Results: A total of 5751 individuals were tested for HTLV antibodies at 8 sites. Donors represented 2312(42.2%), of whom 17 (0.3%) were living kidney donors. The remaining 3439 (59.8%) were recipients. Spaniardsrepresented nearly 80%.Overall, 9 individuals (0.16%) were initially reactive for HTLV antibodies. Six were donors and 3 were recipients.Using confirmatory tests, HTLV-1 could be confirmed in only two donors, one Spaniard and another fromColombia. Both kidneys of the Spaniard were inadvertently transplanted. Subacute myelopathy developedwithin 1 year in one recipient. The second recipient seroconverted for HTLV-1 but the kidney had to beremoved soon due to rejection. Immunosuppression was stopped and 3 years later the patient remains indialysis but otherwise asymptomatic.Conclusion: The rate of HTLV-1 is low but not negligible in donors/recipients of solid organ transplants inSpain. Universal HTLV screening should be recommended in all donor and recipients of solid organtransplantation in Spain. Evidence is overwhelming for very high virus transmission and increased risk alongwith the rapid development of subacute myelopathy PB BMC SN 1471-2334 YR 2019 FD 2019-08 LK http://hdl.handle.net/10498/21716 UL http://hdl.handle.net/10498/21716 LA eng DS Repositorio Institucional de la Universidad de Cádiz RD 17-nov-2026